Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy.

Trial Profile

Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Nilotinib (Primary) ; Peginterferon alfa-2b
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms TIGER
  • Most Recent Events

    • 11 Dec 2013 New source identified and integrated (German Clinical Trials Register: DRKS00005243)
    • 01 Sep 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2010-024262-22)
    • 20 Aug 2012 Planned initiation date changed from 1 Aug 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top